購物車 
-
Apomine
- names：
tetraisopropyl (2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethane-1,1-diyl)bis(phosphonate)
- CAS號：
126411-13-0
MDL Number： - MF(分子式)： C28H52O7P2 MW(分子量)： 562.6645
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規格 | 純度 | 價格 (￥) | 現價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|
| 中文別名 | Apomine |
| 英文別名 | Apomine; APB-231-A-2; SK&F-99085; SR-45023A; SR-9223i; APB-231-A2; SK&F99085; SR45023A; SR9223i. |
| CAS號 | 126411-13-0 |
| Inchi | InChI=1S/C28H52O7P2/c1-18(2)32-36(30,33-19(3)4)25(37(31,34-20(5)6)35-21(7)8)17-22-15-23(27(9,10)11)26(29)24(16-22)28(12,13)14/h15-16,18-21,25,29H,17H2,1-14H3 |
| InchiKey | YLJOVCWVJCDPLN-UHFFFAOYSA-N |
| 分子式 Formula | C28H52O7P2 |
| 分子量 Molecular Weight | 562.6645 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產品說明 | Apomine(CAS:126411-13-0):僅限應用于工業或者科學研究過程中非醫療目的，不應用于人類或動物的臨床診斷以及治過程療，該產品非藥用，非食用。 |
| Introduction | Apomine, also known as APB-231-A-2; SK&F-99085; SR-45023A; SR-9223i, is an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Apomine accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Ang ZY, Boddy M, Liu Y, Sunderland B. Stability of apomorphine in solutions containing selected antioxidant agents. Drug Des Devel Ther. 2016 Oct 3;10:3253-3265. PubMed PMID: 27757015. |
| [2]Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer. 2012 Feb 1;118(3):750-60. doi: 10.1002/cncr.26336. PubMed PMID: 21751201. |
| [3] Kuehl PJ, Stratton SP, Powell MB, Myrdal PB. Preformulation, formulation, and in vivo efficacy of topically applied apomine. Int J Pharm. 2009 Dec 1;382(1-2):104-10. doi: 10.1016/j.ijpharm.2009.08.016. PubMed PMID: 19699284; PubMed Central PMCID: PMC2783960. |
| [4] Roelofs AJ, Edwards CM, Russell RG, Ebetino FH, Rogers MJ, Hulley PA. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Pharmacol Exp Ther. 2007 Jul;322(1):228-35. PubMed PMID: 17412884; PubMed Central PMCID: PMC2820734. |
| [5] Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer. 2007 Apr 15;120(8):1657-63. PubMed PMID: 17230522. |
6: Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP. Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Invest New Drugs. 2007 Apr;25(2):107-14. PubMed PMID: 17024575.7: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed PMID: 17003851.8: Lewis KD, Thompson JA, Weber JS, Robinson WA, O'Day S, Lutzky J, Legha SS, Floret S, Ruvuna F, Gonzalez R. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan;24(1):89-94. PubMed PMID: 16379038.9: Kuehl PJ, Angersbach BS, Stratton SP, Myrdal PB. Development of an HPLC method for the analysis of Apomine in a topical cream formulation. J Pharm Biomed Anal. 2006 Mar 3;40(4):975-80. PubMed PMID: 16181759.10: Elmore E, Siddiqui S, Navidi M, Steele VE, Redpath JL. Correlation of in vitro chemopreventive efficacy data from the human epidermal cell assay with animal efficacy data and clinical trial plasma levels. J Cell Biochem. 2005 Jun 1;95(3):571-88. PubMed PMID: 15786488.1
對不起，暫無產品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養基內，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養耗材技術領先性
細胞培養板行業面臨的核心痛點是：常規TC處理后表面親水角隨時間衰減，影響長期培養穩定性，BIOFOUNT高分...
2026/4/28 15:12:51
細胞培養耗材關鍵性能
細胞培養板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術與國際市場的雙重突破
在實驗室耗材領域，封口膜是保障實驗準確性與穩定性的關鍵產品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領域的國產技術突破和品牌突破，是生物領域中國技術發展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環節，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
